Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer

被引：34
|
作者：
Awad, Mark M. [1 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 08期
关键词：
SARCOMATOID CARCINOMA; AMPLIFICATION; CRIZOTINIB; GEFITINIB; PATIENT; CBL; UBIQUITINATION; RESPONSIVENESS; CHEMOTHERAPY; SENSITIVITY;
D O I：
10.1200/JCO.2015.64.2777
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：879 / +
页数：5
相关论文
共 50 条
  • [31] The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
    Salgia, Ravi
    Sattler, Martin
    Scheele, Juergen
    Stroh, Christopher
    Felip, Enriqueta
    CANCER TREATMENT REVIEWS, 2020, 87
  • [32] Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer
    Wang, Mengchao
    Zhang, Shao
    Yi, Dan
    Ou, Yan
    Xie, Shuqi
    Zeng, Chuanxiu
    Qin, Xueqian
    Zhao, Lu
    Wang, Zhen
    Kong, Fanming
    Chen, Liwei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2025, 151 (02)
  • [33] Cytomorphology of Non-Small Cell Lung Carcinoma with MET Exon 14 Skipping Mutations
    Labiano, Tania
    Echegoyen, Ana
    Moneo, Marta
    Elizalde, Jesus
    Guerrero, David
    LABORATORY INVESTIGATION, 2024, 104 (03) : S438 - S439
  • [34] Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis
    Zhang, Nan
    Xie, Fubo
    Gao, Wei
    Yu, Shuwen
    Qiu, Liyun
    Lin, Wenli
    Sun, Yuping
    Jia, Tanghong
    MOLECULAR MEDICINE REPORTS, 2015, 11 (04) : 2797 - 2804
  • [35] Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
    Chen, Rui-Lian
    Zhao, Jun
    Zhang, Xu-Chao
    Lou, Na-Na
    Chen, Hua-Jun
    Yang, Xue
    Su, Jian
    Xie, Zhi
    Zhou, Qing
    Tu, Hai-Yan
    Zhong, Wen-Zhao
    Yan, Hong-Hong
    Guo, Wei-Bang
    Wu, Yi-Long
    Yang, Jin-Ji
    BMC CANCER, 2018, 18
  • [36] Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
    Rui-Lian Chen
    Jun Zhao
    Xu-Chao Zhang
    Na-Na Lou
    Hua-Jun Chen
    Xue Yang
    Jian Su
    Zhi Xie
    Qing Zhou
    Hai-Yan Tu
    Wen-Zhao Zhong
    Hong-Hong Yan
    Wei-Bang Guo
    Yi-Long Wu
    Jin-Ji Yang
    BMC Cancer, 18
  • [37] Crizotinib in advanced non-small-cell lung cancer with de novo c-Met overexpression.
    Li, An Na
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] C-MET inhibitors for advanced non-small cell lung cancer
    Pasquini, Giulia
    Giaccone, Giuseppe
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (04) : 363 - 375
  • [39] Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.
    Minne, Rachel
    Luo, Natalie
    Traynor, Anne M.
    Huang, Minxuan
    De Tullio, Luisina
    Godden, Jen
    Stoppler, Melissa Conrad
    Kimple, Randall J.
    Baschnagel, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective
    Subramanian, Janakiraman
    Tawfik, Ossama
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (08) : 877 - 886
12345